Form 4 Tracker
Jane Henderson

Chief Financial Officer · 6 filings · Latest: May 1, 2026

Apogee Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
APGE
Jane HendersonChief Financial OfficerMay 1, 2026
Sale
$82.042,000$164.1K173,371
APGE
JANE HENDERSONMay 1, 2026
Proposed Sale
$82.892,000$165.8K
APGE
Jane HendersonChief Financial OfficerApr 16, 2026
Sale
$90.002,000$180.0K175,371
APGE
Jane HendersonChief Financial OfficerApr 1, 2026
Sale
$85.012,000$170.0K177,371
APGE
Jane HendersonChief Financial OfficerMar 25, 2026
Sale
$85.002,000$170.0K179,371
APGE
JANE HENDERSONMar 25, 2026
Proposed Sale
$73.006,000$438.0K
APGE
Jane HendersonChief Financial OfficerMar 2, 2026
Sale
$70.222,000$140.4K181,371
APGE
Jane HendersonChief Financial OfficerFeb 2, 2026
Sale
$65.812,000$131.6K183,371
APGE
JANE HENDERSONJan 2, 2026
Proposed Sale
$75.4812,000$905.8K
APGE
JANE HENDERSONDec 19, 2025
Proposed Sale
$77.351,500$116.0K
APGE
JANE HENDERSONDec 4, 2025
Proposed Sale
$74.551,500$111.8K
APGE
JANE HENDERSONNov 25, 2025
Proposed Sale
$67.851,500$101.8K
APGE
JANE HENDERSONNov 14, 2025
Proposed Sale
$62.972,000$125.9K
APGE
JANE HENDERSONNov 11, 2025
Proposed Sale
$56.771,000$56.8K
AKRO
JANE HENDERSONAug 12, 2025
Proposed Sale
$47.463,000$142.4K
APGE
JANE V HENDERSONAug 23, 2024
Proposed Sale
$48.266,000$289.6K